Skip to main content

Table 4 Progression-free and overall survival of RET+ versus RET- cohorts from start of first-line therapy

From: Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States

Primary analysis, adjusted for covariates at the start of first line therapy
Outcome N Hazard Ratio, HR (95% confidence interval, CI) P-value*
Adjusted analyses
 Progression-free survival (PFS) 5807 1.24 (0.86, 1.78) 0.25
 Overall survival (OS) 5807 1.52 (0.95, 2.43) 0.08
 PFS, Pembro + PC (KN-189 regimen) 674 1.07 (0.44, 2.61) 0.89
 OS, Pembro + PC 674 1.54 (0.36–6.62) 0.56
Unadjusted analyses
 PFS 5807 1.40 (0.99–2.00) 0.06
 OS 5807 1.91 (1.22–3.00) 0.005
 PFS, Pembro + PC 5807 1.01 (0.45–2.27) 0.98
 OS, Pembro +PC 5807 1.92 (0.48–7.72) 0.36
Sensitivity analyses
 PFSa 5807 1.23 (0.86–1.78) 0.26
 OSa 5807 1.53 (0.96–2.44) 0.08
 PFSb 5807 1.27 (0.88–1.84) 0.20
 OSb 5807 1.56 (0.98–2.50) 0.06
 PFSc 5807 1.24 (0.86–1.78) 0.26
 OSc 5807 1.53 (0.95–2.44) 0.08
 PFSd 3615 1.10 (0.67–1.82) 0.71
 OSd 3615 1.47 (0.78–2.75) 0.23
  1. * Multivariable regression, adjusted for age, sex, race, practice type (academic or community), body weight, body mass index (BMI), stage at initial diagnosis, tumor histology, smoking status, microsatellite instability (MSI) status, genomic alterations, Eastern Cooperative Oncology Group (ECOG) performance status, PD-L1 expression (positive = > 1% staining versus negative), initial treatment regimen, and reported metastatic sites
  2. aCovariate of therapy received: Checkpoint inhibitor (ICI) monotherapy vs ICI combination therapy vs other treatments
  3. bCovariate of therapy received Checkpoint inhibitor (ICI) monotherapy vs ICI combination therapy vs biologic therapy vs other treatments
  4. cNot including therapy received as a covariate
  5. dExcluding missing variables
  6. KN-189 first-line treatment with pembrolizumab (pembro) + pemetrexed + platinum (PC)
\